TY - BOOK AU - Heidenreich,Kim A. TI - New therapeutics for traumatic brain injury: prevention of secondary brain damage and enhancement of repair and regeneration SN - 9780128027011 AV - RC387.5 U1 - 617.4810443 23 PY - 2017///] CY - London PB - Academic Press is an imprint of Elsevier KW - Brain damage KW - Treatment KW - Rehabilitation KW - Brain KW - Wounds and injuries KW - Complications KW - Brain Injuries, Traumatic KW - drug therapy KW - complications KW - drug effects KW - Clinical Trials as Topic KW - Cerveau KW - Lésions et blessures KW - Traitement KW - Complications et séquelles KW - MEDICAL / Neurology KW - bisacsh KW - fast KW - Electronic books KW - NATCOLCK N1 - Includes bibliographical references and index; Part I: Interventional therapies for TBI previously or currently in phase 3 clinical trials. Why did the phase III clinical trials for progesterone in TBI fail? An analysis of three potentially critical factors; D.G. Stein, R.B. Howard, I. Sayeed --; Hypothermia for traumatic brain injury: current evidence and future directions; H. Mtaweh, D. Simon, M.J. Bell --; The future of TBI: hyperbaric oxygen as a primary therapeutic approach; B. Miskin, L.A. Fox --; Part II: Repurposing FDA approved drugs for TBI treatment. Erythropoietin and its derivatives: mechanisms of neuroprotection and challenges in clinical translation; T. Bogoslovsky, J.D. Bernstock, K. Kenney, C. Moore, R. Diaz-Arrastia --; Atorvastatin in the treatment of traumatic brain injury; A.N. Sen, S.P. Gopinath, C.S. Robertson --; The application of glibenclamide in traumatic brain injury; D.S. Hersh, J.M. Simard, H.M. Eisenberg --; Perispinal etanercept for traumatic brain injury; E. Tobinick, H. Rodriguez-Romanacce, R. Kinssies, N. Kim --; Part III: Interventional drugs for TBI in phase 1-2 clinical trials. Nitric oxide synthase inhibitors in traumatic brain injury; R. Schinzel, F. Tegtmeier --; Management of paroxysmal sympathetic hyperactivity after traumatic brain injury; L.D. Wilson, T.C. Leath, M.B. Patel --; Part IV: Interventional drugs for TBI in preclinical development. The use of estrogen for the treatment of traumatic brain injury; W.J. Hubbard, I.H. Chaudry --; Voltage-gated calcium channel blockers for the treatment of traumatic brain injury; G.G. Gurkoff, K. Shahlaie, B.G. Lyeth, R.F. Berman --; 5-lipoxygenase-activating protein inhibitors: promising drugs for treating acute and chronic neuroinflammation following brain injury; K.A. Heidenreich, C.E. Corser-Jensen --; Carbonyl scavenging as an antioxidant neuroprotective strategy for acute traumatic brain injury; J.E. Cebak, I.N. Singh, J.A. Wang, R.L. Hill, J.R. Kulbe, E.D. Hall --; TrkB receptor agonist 7,8-Dihydroxyflavone and its therapeutic potential for traumatic brain injury; J. Romeika, M. Wurzelmann, D. Sun --; Ceftriaxone treatment of TBI; M.Q. Hameed, A. Rotenberg --; Part V: Drugs for TBI rehabilitation. Memantine: a safe and tolerable NMDA antagonist with potential benefits in traumatic brain injury; M.A. Keiski --; Interventional drugs for TBI Rehabilitation of cognitive impairment: the cholinesterase inhibitor rivastigmine; M.A. Hernandez-Tejada, O. Brawman-Mintzer --; Docosahexaenoic acid and omega 3 fatty acids; M.E. Schober --; Treatment of mood disorders following traumatic brain injury; H.L. Lin, R.E. Jorge N2 - "New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration explores traumatic brain injury (TBI), a major cause of death and disability throughout the world. The delayed nature of the secondary injury phase suggests that there is a therapeutic window for pharmacological interventions or other approaches to prevent progressive tissue damage and improve functional outcomes. It is now apparent that therapeutic interventions should entail both protective and repair/regeneration strategies depending on the phase of brain injury. This book describes emerging experimental strategies for the treatment of TBI, including new anti-inflammatory or anti-apoptotic therapeutics that limit brain damage, and novel or repurposed drugs that enhance repair or regeneration of the brain after injury"--Publisher's description UR - https://go.openathens.net/redirector/hse.ie?url=https%3a%2f%2fwww.clinicalkey.com%2fdura%2fbrowse%2fbookChapter%2f3-s2.0-C20140023805 ER -